Evidence map›Paper›PMID 30324488›Full record

SynthesisTargeted oncology2018

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.

Francesco Massari, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Riccardo Schiavina, Laura Cosmai, Eugenio Brunocilla, Andrea Ardizzoni, Camillo Porta

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Targeted oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Cytoreductive nephrectomy in metastatic renal cell carcinoma.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma.Indian journal of urology : IJU : journal of the Urological Society of India
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Francesco MassariDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy. fmassari79@gmail.com.ORCID 0000-0001-6476-6871
Vincenzo Di NunnoDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
Lidia GattoDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
Matteo SantoniOncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
Riccardo SchiavinaDepartment of Urology, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy.
Laura CosmaiOnco-Nephrology Outpatients' Clinic, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy.
Eugenio BrunocillaDepartment of Urology, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy.
Andrea ArdizzoniDivision of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
Camillo PortaUniversity of Pavia and IRCCS San Matteo University Hospital, Pavia, Italy.
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITOspedale di MacerataOspedale San Carlo · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC) patients has been common clinical practice due to evidence that resection of the primary tumor results in a survival benefit regardless of systemic treatment. Recently, the first large phase III randomized, non-inferiority prospective clinical trial evaluating this surgical approach demonstrated that systemic treatment alone was not inferior to primary surgery plus systemic treatment.

objectiveOur aim was to evaluate if cytoreductive nephrectomy results in a survival benefit over systemic treatment alone in patients with mRCC and in specific subgroups, including patients with brain metastases, poor performance status, poor prognosis according to IMDC or MSKCC criteria, and clear cell and non-clear cell histologies. PATIENTS AND

methodsWe identified 16 published studies providing complete data for the comparison between cytoreductive nephrectomy + systemic treatment versus systemic treatment alone, and selected 9 for subgroup analysis. The inverse variance technique was applied for the meta-analysis of hazard ratios (HR), and, due to the intrinsic heterogeneity of the data, we adopted a random effects model. Risk of bias among the studies was estimated by the Newcastle-Ottawa Scale (NOS).

resultsOur analysis suggested a survival benefit for patients receiving cytoreductive nephrectomy (pooled HR of 0.48, 95% confidence interval of 0.42-0.56) in the overall population. Survival advantages were also observed in patients with clear cell and non-clear renal cell carcinoma, while no benefit was evident in patients with brain metastasis, poor performance status, and poor risk.

conclusionCytoreductive nephrectomy seems to result in a survival benefit in both clear cell and non-clear cell histology, while no survival advantage was found in patients with specific clinical features. Despite a high level of heterogeneity, our results highlight the importance of a good selection of patients to whom a primary surgical approach could be proposed.

Indexed as

Carcinoma, Renal CellCytoreduction Surgical ProceduresHumansKidney NeoplasmsNephrectomy

Identifiers

PMID30324488
OpenAlexW2896246229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.